US 12,186,563 B2
Method and apparatus for neuromodulation treatments of pain and other conditions
Anatoly Yakovlev, Santa Clara, CA (US); Daniel Pivonka, Del Mar, CA (US); and Logan Palmer, Santa Monica, CA (US)
Assigned to Nalu Medical, Inc., Carlsbad, CA (US)
Filed by Nalu Medical, Inc., Carlsbad, CA (US)
Filed on Feb. 26, 2021, as Appl. No. 17/187,654.
Application 17/187,654 is a continuation of application No. 16/408,989, filed on May 10, 2019, granted, now 10,967,183.
Application 16/408,989 is a continuation of application No. 15/385,729, filed on Dec. 20, 2016, granted, now 10,335,596, issued on Jul. 2, 2019.
Application 15/385,729 is a continuation of application No. PCT/US2015/036821, filed on Jun. 19, 2015.
Claims priority of provisional application 62/077,181, filed on Nov. 8, 2014.
Claims priority of provisional application 62/053,085, filed on Sep. 19, 2014.
Claims priority of provisional application 62/015,392, filed on Jun. 21, 2014.
Prior Publication US 2021/0196957 A1, Jul. 1, 2021
Int. Cl. A61N 1/378 (2006.01); A61B 5/00 (2006.01); A61B 5/0538 (2021.01); A61B 5/11 (2006.01); A61B 5/145 (2006.01); A61B 5/24 (2021.01); A61B 5/389 (2021.01); A61N 1/05 (2006.01); A61N 1/36 (2006.01); A61N 1/372 (2006.01); A61N 2/00 (2006.01); G16H 40/67 (2018.01); H02J 50/00 (2016.01)
CPC A61N 1/36071 (2013.01) [A61B 5/0022 (2013.01); A61B 5/0031 (2013.01); A61B 5/0538 (2013.01); A61B 5/1118 (2013.01); A61B 5/14539 (2013.01); A61B 5/24 (2021.01); A61B 5/389 (2021.01); A61B 5/40 (2013.01); A61B 5/4824 (2013.01); A61B 5/4836 (2013.01); A61N 1/0551 (2013.01); A61N 1/0553 (2013.01); A61N 1/0558 (2013.01); A61N 1/36125 (2013.01); A61N 1/37229 (2013.01); A61N 1/37235 (2013.01); A61N 1/37288 (2013.01); A61N 1/3787 (2013.01); A61N 2/002 (2013.01); A61N 2/006 (2013.01); A61N 2/008 (2013.01); G16H 40/67 (2018.01); A61B 2560/0219 (2013.01); A61B 2560/0242 (2013.01); A61N 1/36007 (2013.01); A61N 1/36057 (2013.01); A61N 1/36064 (2013.01); A61N 1/36067 (2013.01); H02J 50/00 (2016.02)] 18 Claims
OG exemplary drawing
 
1. A neuromodulation apparatus comprising:
an implantable device configured to stimulate tissue, the implantable device comprising:
a resistor configured to measure leakage of the implantable device during a period of non-stimulation to provide single-point failure protection for the implantable device;
a first current source; and
a second current source,
wherein the implantable device is configured to ensure charge balance safety in stimulating the tissue by maintaining an active charge balance between the first and second current sources by matching the first and second current sources to operate in an H-bridge-like configuration, and
wherein the second current source is weaker than the first current source and a stimulation current of the tissue is determined by a current of the second current source; or
wherein the first and second current sources are cascoded and have parallel impedances of at least 1 Mohm.